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Abstract 22 
Vincristine (VCR) treatment is often associated to painful neuropathy. Its 23 
development is independent from antitumoral mechanism and involves 24 
neuroinflammation. We investigated the role of the chemokine prokineticin (PK)2 in a 25 
mouse model of VCR induced neuropathy using a PK-receptors (PK-R) antagonist to 26 
counteract its development. We also evaluated emotional like deficits in VCR mice.  27 
VCR (0,1 mg/kg) was i.p. injected in C57BL/6J male mice once a day for 14 28 
consecutive days. Pain, anxiety and depressive like behaviors were assessed in 29 
animals. PK2, PK-Rs, cytokines, neuroinflammatory markers (CD68, CD11b, GFAP, 30 
TLR4) and ATF3 were evaluated in DRG, spinal cord, prefrontal cortex and 31 
hippocampus. The PK-Rs antagonist PC1, was s.c. injected (150μg/kg) twice a day 32 
from day 7 (hypersensitivity state) until day 14. Its effect on pain and 33 
neuroinflammation was evaluated. 34 
VCR mice developed neuropathic pain but not mood alterations. After 7 days of VCR 35 
treatment we observed a neuroinflammatory condition in DRG with high levels of PK-36 
Rs, TLR4, CD68, ATF3 and IL-1 without relevant alterations in spinal cord. At day 37 
14, an upregulation of PK system and a marked neuroinflammation was evident also 38 
in spinal cord. Moreover, at the same time, we observed initial alterations in 39 
supraspinal brain areas. PC1 treatment significantly counteracted neuropathic pain 40 
and blunted neuroinflammation.  41 
Highlights 42 
Vincristine treated mice develop neuropathic pain but not mood alterations. 43 
Prokineticins are involved in the progression and worsening of hypersensitivity.  44 
Prokineticin antagonism counteracts pain and neuroinflammation. 45 
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PK system is a promising pharmacological target to contrast chemotherapy-induced 46 
neuropathy. 47 
 48 
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1. Introduction 67 
Vincristine (VCR) is one of the most common antineoplastic drugs for the treatment 68 
of several cancer types i.e. leukemia, lymphoma and sarcoma (Gidding et al., 1999). 69 
However, its clinical use is related to several side effects, including peripheral 70 
neuropathy, thus leading to treatment discontinuation. VCR antineoplastic effect is 71 
based on the disaggregation of tubulin monomers during mitosis that inhibits cell 72 
division (Lobert et al., 1996; Martino et al., 2018). It is now accepted that the 73 
development of peripheral neuropathy is not strictly related to drug primary 74 
antitumoral effect, but converges on common several downstream pathways 75 
involving different players (Carozzi et al., 2015; Boyette-Davis et al., 2015). A crucial 76 
role of non-neuronal cells, like macrophages and glial cells, is now recognized and 77 
several studies suggest an association between increased macrophage infiltration in 78 
dorsal root ganglia (DRG) and peripheral nerves and pain like behavior appearance 79 
in experimental animals (Peters et al., 2007; Kiguchi et al., 2009; Montague and 80 
Malcangio, 2017). In particular in CIPN activated macrophages and glial cells, like 81 
microglia and astrocytes, have been shown to release proinflammatory cytokines 82 
and chemokines such as IL-1, TNF, IL-6, CCL2 and CXC family members 83 
(Ledeboer et al., 2007; Kiguchi et al., 2008; Muthuraman et al., 2011; Montague et 84 
al., 2018), leading to neural excitability and pain transmission enhancement. 85 
Furthermore, the same cytokines, when increased in the supraspinal areas, i.e. 86 
prefrontal cortex and hippocampus, can start and sustain a neuroinflammatory 87 
condition related to the presence of altered affective-like or cognitive behavior 88 
(Haroon and Miller 2017; Dantzer 2018; Pfau et al., 2018; Bhattacharya and Jones, 89 
2018; Santos and Pyter, 2018;). Both pain and antitumoral drugs can play a role in 90 
the development of altered affective behavior; in fact patients with chronic pain or 91 
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receiving chemotherapy often experience changes in mood, including the presence 92 
of anxiety and depression, that further impact their life quality. (Wefel and Schagen, 93 
2012; Santos and Pyter, 2018). In accordance with the above described crucial role 94 
of the neuroinflammatory component in CIPN, we recently suggested (Moschetti et 95 
al., 2019) a role of the newly discovered chemokine family, the prokineticin (PK) 96 
family in the peripheral neuropathy induced by the proteasome inhibitor bortezomib 97 
(BTZ). PK family is composed by two proteins: PK1 and PK2 and by two G protein 98 
coupled receptors, PK-R1 and PK-R2. PK-Rs are widely distributed in pain stations 99 
like DRG and spinal cord. In DRG PK-R1 and PK-R2 are expressed in different types 100 
of neurons: in particular, PK-R1, is mainly expressed on small nociceptors while PK-101 
R2 is expressed on medium and large-sized neurons (Negri et al., 2007; Negri and 102 
Maftei, 2018). In the spinal cord, the highest density for PK-Rs is within the dorsal 103 
horns suggesting that these receptors might be involved in central transmission of 104 
the nociceptive signal (Negri and Lattanzi, 2012). In non neuronal cells, such as 105 
astrocytes and microglia PK-R1 is mostly expressed. Moreover, this receptor is more 106 
abundant than PK-R2 also on human and rodent monocytes/macrophages. 107 
It is known that PK-Rs may be  coupled to Gq, Gi, and Gs (Lin et al., 2002; Soga et 108 
al., 2002) depending on their cellular localization and can activate different 109 
intracellular signal pathways (for an explicative review, see Negri and Ferrara, 2018). 110 
In the monocytes/macrophage/microglia lineage, in DRG and spinal cord they are 111 
Gq-coupled receptors and promote intracellular Ca2+ mobilization through the 112 
activation of phospholipase C (PLC) and formation of IP3. In the DRG, PKR 113 
activation, via Gq, increases intracellular calcium and induces protein kinase C 114 
(PKC)- translocation to the plasma membrane (Vellani et al., 2006). Regarding the 115 
ligands, PK2 is recognized as an important player at cross road between 116 
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inflammation and pain (Franchi et al., 2017) while PK1, that is not expressed in DRG 117 
and spinal cord, is more involved in angiogenesis. It is known that PK2 can modulate 118 
the immune function inducing a proinflammatory phenotype and sustaining a 119 
proinflammatory condition (Martucci et al., 2006). Moreover, it sensitizes TRPV1 and 120 
TRPA1-expressing nociceptors (Negri et al., 2006; Vellani et al., 2006) and induces 121 
the release of proinflammatory/ pro-algogen mediators like cytokines, Substance P 122 
(SP) and CGRP. Furthermore, PK2 is involved in the development of experimental 123 
neuropathic pain (Maftei et al., 2014; Guida et al., 2015; Castelli et al., 2016) of 124 
different origin, including BTZ induced neuropathy. 125 
Interestingly, a role for PK2 in mood regulation has also been described. 126 
Intracerebroventricular injection of PK2 leads to increase of anxiety and depressive 127 
like behavior while mice deficient in PK2 display reduced anxiety and depression (Li 128 
et al., 2009). 129 
Considering the above described involvement of PK2 in the development of 130 
experimental pain and anxiety/depressive like behavior, the present study aims to: 131 
 assess the role of PK system in vincristine (VCR) induced peripheral 132 
neuropathy and verify if the blockade of PK-Rs can counteract VCR induced 133 
hypersensitivity, representing a generalized strategy to contrast 134 
chemotherapy-induced neuropathy, 135 
 verify if, in our experimental model of VCR induced neuropatic pain, the 136 
presence of hypersensitivity is related to the presence of altered affective 137 
behaviors. 138 
 139 
 140 
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2. Materials and Methods 141 
An explicative timeline of the experimenthal design is shown in Figure 1. 142 
2.1 Animals 143 
Male C57BL/6J mice (Charles River Laboratories, Calco, Italy), nine-weeks-old, were 144 
individually housed with 12 hours light/dark cycles, temperature of 22 ± 2 °C, 145 
humidity of 55 ± 10%, food and water ad libitum. Animals were acclimatized to the 146 
environment for ten days and subsequently handled (exposure to a passive hand, 147 
tickling, hand restraint for few minutes) for 3 consecutive days before starting the 148 
experiments. All animal experiments comply with ARRIVE guidelines and were 149 
carried out in accordance with EU directive 2010/63/EU for animal experiments and 150 
were approved by the Animal Care and Use Committee of the Italian Ministry of 151 
Health (permission number 709/ 2016 to SF). 152 
2.2 Drugs 153 
Mice were randomly divided in two experimental groups, controls (CTR) and 154 
vincristine (VCR) treated mice by using the physical method of coin flipping. 155 
Vincristine sulfate (TOCRIS Bioscience™, Minneapolis, USA), diluted in saline 156 
solution (0,9% NaCl) was intraperitoneally (i.p) injected at the dose of 0,1 mg/kg/ day 157 
for 14 consecutive days. The vincristine dose was assumed from the literature 158 
(Kiguchi et al., 2008). The schedule treatment allows to induce a detectable painful 159 
neuropathy minimizing unspecific systemic toxicity and preventing mice death. 160 
Control mice were treated with saline solution. 161 
VCR neuropathic mice were randomly selected (coin flipping method) for PK-Rs 162 
antagonist (PC1) treatment. PC1, a triazine guanidine derivative selective for PK-Rs 163 
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(Balboni et al., 2008), was firstly dissolved in DMSO 10% and then subcutaneously 164 
administered at the dose of 150 µg/kg, diluted in saline solution, two times/day for 7 165 
consecutive days: from day 7 until the end of the VCR schedule (day 14). The 166 
chosen dose represents the most effective one in contrasting pain on the basis of the 167 
results of a dose-finding study performed in CCI neuropathic mice (Maftei et al., 168 
2014). The same dose was also effective in other neuropathic pain models like nerve 169 
injury model (SNI), streptozotocin induced diabetes and bortezomib induced 170 
peripheral neuropathy (Guida et al., 2015; Castelli et al., 2016; Moschetti et al., 171 
2019). In order to minimize possible interactions between the two drugs, mice were 172 
always treated with VCR early in the morning (around 8:00 a.m.) and  they were then 173 
treated with PK-Rs antagonist around 12:00 p.m. for the first injection and at 6:00 174 
p.m. for the second PC1 administration. The effect of PC1 on nociception and 175 
related biochemical parameters (cytokines, PK2 and PK-Rs in nervous tissues) in 176 
naïve mice has been previously charaterized (Castelli et al., 2016; Maftei et al., 177 
2014; Giannini et al., 2009) showing that the antagonist alone did not affect these 178 
aspects in normal mice. Therefore according to 3R guidelines we did not include this 179 
experimental group in the present work. 180 
2.3 Behavioral evaluations 181 
2.3.1 Pain-related behavioural evaluations 182 
All behavioral evaluations were performed by researchers blind to treatments. 183 
Behavioral tests were performed after an habituation period of 30 minutes. 184 
Responses to mechanical and thermal stimuli were assessed before starting VCR 185 
protocol (0), and after 3, 7, 11 and 14 days of chronic VCR treatment. Considering 186 
the time span of the acute effect of PC1 (Castelli et al., 2016; Moschetti et al., 2019), 187 
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to test the effect of the chronic treatment with PC1, all behavioral tests (day 11 and 188 
14) were performed at least 12 hours after the last injection of the antagonist. 189 
For hypersensitivity tests for each mouse we performed three different 190 
measurements on each hind-paw, the values were then averaged obtaining a single 191 
value. The values obtained from each mouse of the same experimental group were 192 
then averaged and used for statistical analysis.  193 
2.3.1.1 Von Frey Test 194 
Mechanical allodynia was monitored evaluating the mechanical touch sensitivity 195 
through a blunt probe (Von Frey filament, 0.5 mm diameter) on the mid plantar 196 
surface of the animal hind paw, using the Dynamic Plantar Aesthesiometer (Ugo 197 
Basile, Comerio, Italy). Animals were placed in a plexiglass test cage (w 8.5 x  h 8.5 198 
cm ) upon a metallic mesh and the rigid tip of a Von Frey filament (punctate stimulus) 199 
was applied to the skin of the mid-plantar area of the hind paw with increasing force 200 
(ranging up to 10 g in 10 s), starting below the threshold of detection and increasing 201 
until the animal feels pain and it removes its paw. The withdrawal threshold (PWT) 202 
was expressed in grams.  203 
2.3.1.2 Acetone Drop Test 204 
Cold allodynia was evaluated as previously described (Flatters and Bennet, 2004; 205 
Brini et al., 2017; Moschetti et al., 2019). A drop (50 μl) of acetone was placed in the 206 
middle of the plantar surface of the hind paw and mouse behavior was initially 207 
monitored, inside a plexiglass arena (h50 x w 40), for 20 s. If mice did not withdraw, 208 
flick or stamp the hind paw within this time lapse, no other observations were made 209 
and the researcher assigned the score 0 to mice. However, if within this period the 210 
animal responded to the cooling effect of acetone, its behavior was assessed for an 211 
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additional 20 s. Responses to acetone were graded (allodynia score), using a 4 212 
points scale, as follow: 0, no response; 1, quick withdrawal, flick or stamp of the paw; 213 
2, prolonged withdrawal or repeated flicking (more than twice) of the paw; 3, 214 
repeated flicking of the paw with licking directed at the plantar surface of the hind 215 
paw. 216 
2.3.1.3. Plantar Test 217 
Thermal hyperalgesia was tested according to the Hargreaves procedure 218 
(Hargreaves et al, 1988) slightly modified by us for mouse (Franchi et al., 2012), 219 
using a Plantar test apparatus (Ugo Basile, Comerio, Italy). Briefly, mice were placed 220 
in a plexiglass cubicles (w 11 x  h 11  cm ) and a constant intensity radiant heat 221 
source (beam diameter 0.5 cm and intensity 20 I.R.) was aimed at the mid plantar 222 
area of the hind paw until the animal removed its paw. Paw withdrawal latency 223 
(PWL) that is the time, in seconds (s), from initial heat source activation until paw 224 
withdrawal was recorded.  225 
2.3.2 Mood-related behavioural evaluations 226 
Mice were randomly divided (coin flipping) in two cohorts to assess the presence of 227 
anxiety or depressive like behavior associated to VCR treatment. In this way half of 228 
the animals underwent tests to assess the development of depression-like 229 
phenotypes (Depression-like Cohort) and the other half tests to measure anxiety-like 230 
behaviors (Anxiety-like Cohort).Anxiety and depression were assessed at the end of 231 
VCR schedule (day 14). Mice were habituated in the testing room for 1 hour. 232 
Evaluations were performed/ analysed by researchers blind to treatments.  233 
Anxiety-like behavior  234 
2.3.2.1 Open Field Test (OFT) 235 
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Open field test was performed to score the mice locomotor activity. Mice were placed 236 
in an unfamiliar open arena (40x40x50 cm) and allowed to freely explore for 10 min. 237 
After this session they were returned to their cages. The same protocol was used for 238 
the baseline measurement and the test session (day 14). The session was recorded 239 
and then the videos were analyzed by three experimenters blind to the treatment. 240 
The mobility of the mice was scored during the entire session. 241 
2.3.2.2 Marble Burying Test 242 
Cages were filled with approximately 5cm deep with wood chip bedding, lightly 243 
tamped down to make a flat surface. A regular pattern of 18 glass marbles was 244 
placed on the surface, evenly spaced, each about 3cm apart. Mouse was placed in 245 
each cage and left in it for 30 minutes. After this time span, mouse was put back in 246 
its cage and the number of  marbles buried with bedding (2/3 their depth) was 247 
counted (Deacon, 2006). 248 
2.3.2.3 Novelty Suppressed Feeding (NSF) 249 
The test was performed by scoring the latency to feed for a food-deprived mouse 250 
when it is introduced to an unfamiliar and adversive environment. Briefly, prior to the 251 
test, individually housed mice were subjected to a 24h food deprivation. Mice were 252 
weighed before and after the food deprivation to check differences in the loss of the 253 
body weight between experimental groups. Novelty-suppressed feeding assay was 254 
performed in a open arena with bedding covering the floor and a food pellet in the 255 
center, placed on a Petri dish under bright light. Each mouse was removed from its 256 
home cage, weighed, and introduced to one corner of the arena. The mouse was 257 
allowed to freely investigate the arena and the food for a maximum of 5 min. Feeding 258 
behavior was recorded by a video camera and the latency to biting the food was 259 
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scored later by two experimenters blind to the treatment. Once the mouse bit the 260 
food, it was quickly transferred to the home cage with a new pre-weighed pellet of 261 
food. The mouse was undisturbed in the home cage for 5 min and then the food was 262 
removed and weighed again. 263 
2.3.2.4 Dark/Light Box (DLB) 264 
The test was conducted in a two-chamber arena (40x40x50 total cm) with a black 265 
divider. The light chamber measures 28x40x50 cm while the dark chamber 266 
12x40x50. An opening was located at the center bottom of the divider. The walls of 267 
dark chamber were made of black plexiglass while those of the other chamber were 268 
white. The lid of the dark box was made of a black plexiglass. During the test mice 269 
were first placed into the dark chamber and allowed to freely travel between the 270 
chambers for 5 min. The entire session was video recorded and later analyzed by 271 
three experimenters blind to the treatment. The time spent in the light chamber, and 272 
the number of transitions (defined as the times the animal passes in or out of the 273 
light and dark chambers) were scored. 274 
Depressive-like behavior  275 
2.3.2.5 Forced Swim Test (FST) 276 
The assay was performed using a standard protocol of forced-swim test for mice to 277 
test the “behavioral despair” at the end of the treatment. Briefly, a 3L glass beaker 278 
(14.5 cm diameter, 27 cm height) filled with water (23-25 °C) was used as apparatus. 279 
Mice were placed in the beaker and allowed to swim undisturbed for 6 min. The 280 
animals were then removed, dried, and returned to their home cages. Water was 281 
changed between each subject. The entire session was recorded with a video 282 
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camera. Later, the videos were scored by three experimenters blind to the treatment 283 
for the duration of immobility during the last 4 min of the session. 284 
2.3.2.6 Sucrose Preference Test (SPT) 285 
Sucrose preference test was used as in indicator of anhedonia. During habituation, 286 
mice were given 48 hours of continuous exposure to two regular bottles, both 287 
containing tap water (regular water), in their home cages with ad libitum access to 288 
food. Mice were then exposed to two bottles (sucrose/water during baseline 289 
measurements and sucrose preference test and water/water for the remaining days) 290 
in their home cage during all the experiment. After the habituation, sucrose 291 
consumption baseline was measured one week before vincristine treatment, in two 292 
consecutive sessions during the dark phase. In the baseline measurement stages, 293 
each mouse was given one bottle of 2% sucrose solution and one of regular water 294 
for 16 hours (6 P.M. to 10 A.M.). Mice were tested at the end of vincristine treatment 295 
with two consecutive 16 hours sessions during the dark phase. During the test, all 296 
animals were exposed to one bottle of 2% sucrose solution and one of regular water, 297 
both weighed before and after the test and switched in the position to reduce any 298 
confound produced by a side bias. Sucrose preference was calculated as a 299 
percentage of the volume of sucrose intake over the total volume of fluid intake for 300 
each tested animal. 301 
2.4 Tissue collection 302 
After 7 days of chronic VCR treatment and the end of VCR/PC1 schedule (day 14, 303 
VCR) mice were euthanized by CO2 inhalation. DRG (L4-L6), lumbar (L4-L6) spinal 304 
cord, prefrontal cortex (PFC) and hippocampus (HPC) were dissected, frozen in 305 
liquid nitrogen and stored at -80°C until further processing. 306 
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2.5 RNA extraction and RT-qPCR 307 
Total RNA was isolated from DRG (L4-L6), lumbar spinal cords, PFC and HPC using 308 
TRIzol® reagent (Invitrogen, Carlsbad, USA) according to manufacturer’s 309 
instructions and re-suspended in a volume of 10–25 μl, depending on the tissue, of 310 
RNase-free water. RNA quantity and quality was determined using a BioPhotometer 311 
(Eppendorf, Germany). Reverse transcription of mRNA was performed according to 312 
the manufacturer’s instructions (iScript cDNA Synthesis Kit, Bio-Rad).  313 
Gene of interest were analyzed by Reverse transcription quantitative polymerase 314 
chain reaction (RT-qPCR) using the following TaqMan Gene Expression Assays 315 
(Thermofisher Scientific, Waltham, USA): Prokineticin2 (Mm01182450_g1), 316 
Prokineticin receptors (Prokr1 Mm00517546_m1; Prokr2 Mm00769571_m1), 317 
cytokines (TNF-α Mm00443258_m1; IL-6 Mm00446190_m1; IL-1β 318 
Mm00434228_m1; IL-10 Mm00439616_m1;), CD68 (Mm_03047343), CD11b 319 
(Mm00434455_m1), TLR4 (Mm00445274_m1), GFAP (Mm01253033_m1) and 320 
ATF3 (Mm00476033_m1) and glyceraldehydes-3-phosphate dehydrogenase 321 
(GAPDH Mm99999915_g1). Experimental procedures were performed according to 322 
the TaqMan Gene Expression Assays protocol. Each sample was run in duplicates 323 
alongside non-template controls. The PCR cycle protocol used was: 1 min at 95°C, 324 
40 five-step cycles of 15 s at 95°C and 30seconds at 60°C. Threshold cycle numbers 325 
(Ct) of the specific gene of interest and the endogenous control gene GAPDH were 326 
determined by ABI PRISM 7000 Sequence Detection System (AppliedBiosystems®, 327 
Foster City, USA). The Ct value of the specific gene of interest was normalized to the 328 
Ct value of the endogenous control, GAPDH, and the comparative Ct method (2 329 
−ΔΔCt ) was then applied using the specific control group (vehicle treated mice) as 330 
calibrator. 331 
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2.6 Statistical Analysis 332 
Data are expressed as mean± SEM. Results obtained from pain related behavioral 333 
evaluations were analyzed using Two way-ANOVA analysis of variance with 334 
repeated measures (factors: treatments and time) followed by Bonferroni’s test for 335 
multiple comparisons. 336 
Anxiety and depressive like behaviours results and biochemical evaluations 337 
performed at day 7 were analyzed by using unpaired two tails t-test while 338 
biochemical data performed at day 14 were tested using One way-ANOVA followed 339 
by Bonferroni's test. Statistical analysis was performed using GraphPad 6 (San 340 
Diego, CA). Differences were considered significant at p≤ 0.05. 341 
3. Results 342 
3.1 Effect of VCR treatment on hypersensitivity (allodynia and hyperalgesia) 343 
and affective behavior (anxiety and depressive like behavior). Effect of PK-Rs 344 
antagonist (PC1) on hypersensitivity. 345 
VCR induced in mice a progressive reduction of both mechanical and thermal 346 
thresholds. As shown in figure 2 (panels a, b and c) VCR treatment induced in mice 347 
the presence of an allodynic and hyperalgesic state characterized by a significant 348 
reduction of mechanical and thermal thresholds evident from day 3 until the end of 349 
VCR administration (panel a, b and c; CTR vs VCR p< 0.0001).The treatment with 350 
the PK-Rs antagonist PC1 was started in presence of a well-established allodynic 351 
and hyperalgesic state (day 7). As illustrated in panel b, 3 days of chronic PC1 352 
treatment (day 11 VCR) are enough to abolish thermal allodynia (VCR vs VCR+ 353 
PC1, p< 0.0001) while it takes 7 days (day 14 VCR) to completely reverse 354 
mechanical allodynia (panel a, VCR vs VCR+ PC1, p< 0.0001). PC1 was also able 355 
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to significantly counteract hyperalgesia. Its effect is already evident at day 11 (3 days 356 
of PC1;  VCR vs VCR +PC1 p< 0.0001) and is maintained until the end of PC1 357 
schedule (day 14; VCR vs VCR +PC1 p< 0.0001). In this case paw withdrawal 358 
latency of PC1 treated mice were still different from those of CTR mice (panel c; 359 
CTR vs VCR+ PC1 p< 0.0001). 360 
As shown in the same figure, VCR treated mice are not characterized by emotional 361 
alterations (panels d-i). At the end of VCR protocol (day 14) we did not detect in mice 362 
the presence of anxiety-like behavior. No alterations were observed between control 363 
(vehicle) and VCR treated mice in the time spent moving, evaluated in the open field 364 
test (panel d), in the novelty suppressed feeding test measuring both the latency for 365 
eating and the home-cage food consumption (panel e) nor in the number of buried 366 
marbles evaluated by marble burying test (panel f). Moreover, no signs of anxiety 367 
like behaviors were highlighted in the light/dark test (panel g), neither evaluating the 368 
time spent in the light box nor the number of transitions between the two chambers. 369 
In addition, VCR treated mice were similar to CTR mice considering the immobility 370 
time in the forced swim test (panel h) and the percentage of sucrose intake in the 371 
sucrose preference test (panel i), excluding the presence of a depressive like 372 
behavior in VCR treated mice. 373 
3.2 Neuroinflammation assessment in DRG and spinal cord 374 
Biochemical parameters were evaluated before starting PC1 treatment, 375 
corresponding to day 7 of VCR schedule protocol, and at the end of VCR/ VCR 376 
+PC1 treatment (day 14). All evaluations were performed in blind.  377 
 378 
 379 
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3.2.1 PK system (PK2 and PK-Rs) and neuroinflammation in DRG 380 
As shown in figure 3, at day 7 an up-regulation of both PK-R1 (panel b; p= 0.0357) 381 
and PK-R2 (panel c; p= 0.0004) expression levels is already evident in DRG. At day 382 
14, together with high levels of PK-Rs, we also registered increased levels of PK2 383 
(panel a; p= 0.0157). PC1 treatment was able to prevent PK2 increase (panel a; 384 
VCR vs VCR+ PC1 p= 0.0067) and to reduce PK-Rs levels (VCR vs VCR + PC1 p= 385 
0.0082 and p< 0.0001 panels b and c respectively). At day 7 we only observed 386 
changes in the levels of the proinflammatory cytokine IL-1 (panel d, p= 0.0156) 387 
without any change in the other cytokines (panels e-g). Simultaneously, we 388 
measured high levels of TLR4 (panel h, p= 0.0280) and of the marker of macrophage 389 
activation CD68 (panel i, p= 0.0260).  These alterations are associated to the 390 
presence of increased levels of the marker of neuronal damage ATF3 (panel m, p= 391 
0.0005). At the end of VCR protocol (day 14), we registered a significant 392 
neuroinflammatory condition characterized by a marked proinflammatory cytokine 393 
profile due to high levels of IL-1, TNF and IL-6 (panels d, e and f respectively; p= 394 
0.001, 0.0059 and 0.0002) and low levels of the anti-inflammatory cytokine IL-10 395 
(panel g, p= 0.0362). At the same time, TLR4, CD68 and ATF3 (panels h,i and m) 396 
were still upregulated and we also observed a significant increase of CD11b (panel l, 397 
p= 0.0103). PC1 treatment was able to counteract this neuroinflammatory condition, 398 
restoring a correct cytokine balance: reducing IL-1 levels (panel d, VCR vs VCR+ 399 
PC1 p< 0.0001), preventing TNF and IL-6 increase (panels e and f, VCR vs VCR+ 400 
PC1 p= 0.0003 and p< 0.0001) and opposing to IL-10 decrease (panel g, p< 401 
0.0001). Simultaneously the antagonist also normalized the levels of TLR4 (panel h, 402 
VCR vs VCR+ PC1 p= 0.0010), CD68 (panel i, VCR vs VCR+ PC1 p= 0.004) and 403 
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CD11b (panel l, VCR vs VCR+ PC1 p= 0.0236) even if it was unable to reduce ATF3 404 
in a significant way (panel m).405 
SPINAL CORD 406 
3.2.2 PK system (PK2 and PK-Rs), and neuroinflammation in spinal cord 407 
Similarly to DRG, also in spinal cord (figure 4) at day 7 we only observed increased 408 
levels of PK-Rs, both PK-R1 (panel b, p= 0.0127) and PK-R2 (panel c, p=0.0208) 409 
without changes of PK2 (panel a). At the end of VCR protocol (day 14) we measured 410 
an up-regulation of the entire PK system (panels a and b: p= 0.0004, panel c: p= 411 
0.0020). PC1 treatment was able to normalize the levels of all PK system members, 412 
opposing to PK2 upregulation (panel a, VCR vs VCR+PC1 p= 0.0002) and reducing 413 
PK-Rs levels (VCRvs VCR+PC1 p=0.0002 and p< 0.0001, panels b and c). As 414 
shown in the same figure after 7 days of VCR daily treatment we observed a 415 
significant upregulation of CD68 (panel i, p= 0.007) without any other alteration in 416 
cytokines levels (panels d-g), TLR4 (panel h), glial markers (l-m) or ATF3 (panel n). 417 
Differently, at the end of VCR protocol (day 14) we observed increased levels of the 418 
proinflammatory cytokines IL-1 and TNF ( p= 0.0146 and p= 0.0004; panels d and 419 
e respectively), without changes in IL-6 (panel f) and IL-10 (panel g), increased 420 
levels of TLR4 (panel h; p= 0.0383), CD68, CD11b (panels i and l respectively; p= 421 
0.0001 and p= 0.0159), GFAP (panel m, p= 0.0001) and ATF3 (panel n, p= 0.0033). 422 
PC1 treatment could counteract and prevent neuroinflammation maintaining at 423 
control levels the mRNA levels of the cytokines IL-1 and TNF (panels d and e; 424 
VCR vs VCR+PC1 p= 0.0007 and p= 0.0153), TLR4 and CD11b (panels h and l, p= 425 
0.0322 and p= 0.0366) and reducing CD68 and ATF3 levels (panels i and n; p= 426 
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0.0016 and p< 0.0001). PC1 was unable to contrast the increase of GFAP observed 427 
at the higher VCR dose (panel m). 428 
3.3 Evaluation of PK members and neuroinflammation in prefrontal cortex and 429 
hippocampus 430 
Figure 5 shows changes in PK2 and PK-Rs and neuroinflammatory parameters 431 
evaluated at the end of VCR treatment (day 14) in prefrontal cortex (PFC) and 432 
hippocampus (HPC). 433 
As shown in panels a and c, a decrease of PK2 (p= 0.0079) and PK-R2 receptor (p= 434 
0.0225) in PFC of VCR treated mice was evident. PC1 could completely prevent the 435 
down regulation of PK-R2 (panel c; VCR vs VCR+PC1 p= 0.0264; CTR vs VCR+ 436 
PC1 ns). Similarly, we observed a down regulation of PK2 also in HPC (panel a; p= 437 
0.0003) and PC1 treatment significantly prevented it (VCR vs VCR+PC1 p= 0.0002). 438 
As illustrated in the same figure, no significant alterations in the levels of pro/anti-439 
inflammatory cytokines IL-1 (panel d), TNF (panel e), IL-6 (panel f) and IL-10 440 
(panel g) were detected in these two areas. However, we observed in the 441 
hippocampus a significant downregulation of CD68 (panel h; p= 0.0331), CD11b 442 
(panel i; p=0.0287) and GFAP (panel l; p< 0.0001) markers and PC1 treatment was 443 
able to prevent the GFAP decrease (panel l; VCR vs VCR+PC1 p= 0.0007). 444 
4. Discussion 445 
In this study we described a role of PK2 recently recognized as important mediator at 446 
cross roads between inflammation and pain (Franchi et al., 2017), in the progression 447 
of vincristine (VCR) -induced neuropathic pain. We also demonstrated that the 448 
antagonism of PK-Rs completely abolished allodynia in neuropathic mice. This effect 449 
was in part due to the ability of the PK-Rs antagonist, PC1, to contrast 450 
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neuroinflammation in dorsal root ganglia and to prevent its development in the spinal 451 
cord.  452 
Chemotherapy-induced peripheral neuropathy is a frequent side effect of several 453 
antitumoral treatments, its development seems to be independent from drug’s 454 
antitumoral mechanism of action and involves several components i.e. oxidative 455 
stress, mitochondrial damage, TRPV activation and neuroinflammation (Carozzi et 456 
al., 2015; Boyette-Davis et al., 2015). In particular, it was suggested a crucial role of 457 
activated macrophages and glial cells like microglia and astrocytes. These cells can 458 
release several proinflammatory cytokines and chemokines leading to neural 459 
excitability and pain transmission enhancement (Muthuraman et al., 2011; Montague 460 
et al., 2018; Brandolini et al., 2019). In our protocol (Kiguchi et al., 2008) VCR 461 
induced in mice a progressive mechanical and thermal allodynia as well as the 462 
development of thermal hyperalgesia. Our results suggest that after 7 days of 463 
chronic VCR treatment the presence of hypersensitivity is sustained by a 464 
neuroinflammatory condition particularly evident in DRG and not already manifest in 465 
the spinal cord. Therefore, our results confirmed that DRG represents one of the first 466 
direct target of the cytotoxic action of VCR, likely due to drug’s capability to cross the 467 
blood nerve barrier (Hunt et al., 2012). In fact, probably as response to drug’s toxic 468 
insult (Hunt et al., 2012; Hansen et al., 2011), we observed in DRG increased levels 469 
of the marker of neuronal damage ATF3, togheter with high levels of the marker of 470 
macrophage activation CD68, increased levels of TLR4, PK-Rs and IL-1 471 
upregulation.Our data are in accordance with literature that describes a crucial role 472 
of TLR4 and of infiltered macrophages into PNS (Zhang et al., 2016; Montague and 473 
Malcangio 2017; Flatters et al., 2017); once activated these cells release a broad 474 
spectrum of proinflammatory mediators like cytokines and chemokines contributing 475 
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to damage and sensitizing process (Uçeyler et al,  2006; Lees et al., 2017; Montague 476 
et al., 2018; Colvin 2019). At the end of VCR protocol, we registered in the animals a 477 
further lowering of the mechanical and thermal thresholds that was related to a more 478 
pronounced inflammatory profile at DRG level and to the development of a 479 
neuroinflammatory condition clearly evident also in spinal cord. This condition is 480 
sustained by an upregulation of the entire PK system (PK2 and PK-Rs) at both 481 
peripheral and spinal cord level. Although we are aware that a limitation of our study 482 
is that we did not perform an immunohistochemical analysis in the VCR model, we 483 
have deeply investigated the cells associated to PK system in different models of 484 
neuropathic pain in our previous works (Maftei et al., 2014; Guida et al., 2015) 485 
including (Moschetti et al., 2019) in bortezomib induced peripheral neuropathy. 486 
Considering that infiltrating macrophages express PK-Rs receptors (LeCouter et al., 487 
2004), PK2 can act in autocrine or paracrine way sustaining a neuroinflammatory 488 
loop that exacerbate the neuronal damage and promote a progressive glial activation 489 
at the spinal cord level. However, as previously described, other cell types like 490 
satellite glial cells, neurons and astrocytes express PK-Rs and are important source 491 
of PK2 (Maftei et al., 2014; Guida et al., 2015; Moschetti et al., 2019). We could 492 
speculate that the proinflammatory cytokine increase in DRG can trigger the 493 
activation of the transcriptional factor STAT3, which in turn directly binds to the Pk2 494 
promoter (Qu et al. 2012) inducing PK2 increase. On the basis of our results we can 495 
suppose that PK2, differently from the chemokine CX3CR1 (Montague et al., 2018), 496 
is not directly involved in the initial recruitment phase of immune cells in the 497 
damaged tissue, and it is not related to the onset of hypersensitivity, as has been 498 
observed in other neuropathic pain models (Maftei et al., 2014; Guida et al., 2015; 499 
Castelli et al., 2016), In this experimethal model, as already described for bortezomib 500 
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(Moschetti et al., 2019), PK2 has a role in the progression and worsening of a 501 
neuroinflammatory and hypersensitivity state, sustaining a flow of neuroimmune 502 
activation from the periphery to the central nervous system (Scholz and Woolf, 2007; 503 
Kiguchi et al., 2009; Calvo et al., 2012; Sacerdote et al., 2013) which is at the basis 504 
of the development of pathological pain. Chronic therapeutic treatment with PC1 can 505 
block the already started, although still at the beginning, neuroinflammatory process 506 
preventing PK2 upregulation and contrasting a self-sustained inflammatory/ 507 
neuroinflammatory loop that involves also cytokines. The result of this condition is a 508 
complete anti-allodynic effect exerted by PC1 and a partial anti-hyperalgesic one. As 509 
happened in bortezomib induced neuropathy, PC1 fails to counteract the increase of 510 
GFAP in the spinal cord, so we believe that astrogliosis might be responsible of the 511 
only partial anti-hyperalgesic effect of PC1 (Moschetti et al., 2019). We are aware 512 
that we did not provide a resolutive evidence that the effects of PC1 on vincristine-513 
induced pain are only due to its interactions with PK-Rs but several  data can 514 
support this hypotheis.   In particular, when administered alone in healthy mice PC1 515 
did not induce behavioural/biochemical alterations (Castelli et al.2016; Giannini et 516 
al., 2009) and this antagonist did not counteract hypersensitivity induced by 517 
molecules different from PK2, i.e. PGE2, ATP or bradykinin. Other PK-Rs peptidic or  518 
non peptidic antagonsists  exert anti-inflammatory and modulatory effects similar to 519 
those induced by PC1 (Abou-Hamdan et al, 2015; Maftei et al., 2014) and  different 520 
strategies that block PK2 activity, such as antibodies against PK2 prevent pain and 521 
neuroinflammation in a model of cancer pain (Hang et al., 2015).  All these results 522 
seem to indicate that PC1 is effective in  blocking PK2 activity, exogenously 523 
administered or endogenously overexpressed.  524 
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The results here obtained assume a broader meaning because, confirming our 525 
recently published data on bortezomib-induced neuropathy (Moschetti et al., 2019), 526 
suggest that the block of PK system counteracts the activation of intracellular 527 
signaling pathways common to antitumoral drugs characterized by different primary 528 
mechanism of action and responsible for neuropathy development. 529 
Both chronic pain and chemotherapeutics are often, but not always, associated to 530 
altered emotional behavior and impaired cognitive function (Moriarty et al., 2011; 531 
Bushnell et al., 2013; Seigers et al., 2013; Palazzo et al., 2016; Santos and Pyter, 532 
2018; Guimaraes et al., 2018). However some papers suggest a temporal shift 533 
between the presence of the symptoms and the appearance of altered affective 534 
behavior (Dellarole et al., 2014 ; Toma et al., 2017). Also in our experimental 535 
paradigm, in VCR treated animals, pain is not correlated to the presence of any 536 
anxiety or depressive like behavior. Our results demonstrate that 2 weeks of 537 
continuous marked thermal and mechanical hypersensitivity are not associated to 538 
overt mood alteration, suggesting that development of mood/cognitive alteration may 539 
vary according to protocols, timing and models utilized (Karl et al., 2019).  540 
Considering that chemotherapeutics do not or only partially cross the blood brain 541 
barrier, central nervous system has generally been considered to be less vulnerable 542 
to a direct toxic effect of chemotherapy. However, it was suggested that 543 
chemotherapy metabolites or other indirect mechanisms, such as peripheral immune 544 
cell infiltration may have neurobiological consequences (Ahles and Saykin, 2007). In 545 
our experimental protocol we did not find emotional-like deficits in VCR treated 546 
animals and, at the same time, we did not  observe changes in the levels of 547 
proinflammatory cytokines in brain areas generally involved in mood regulation like 548 
prefrontal cortex and hippocampus. These data are in accordance with literature that 549 
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suggests a crucial role of neuroactive cytokines like IL-1, IL-6 and TNF in the 550 
development of a depressive symptomatology (Dantzer 2018; Pfau et al., 2018; 551 
Bhattacharya and Jones, 2018). It was also reported a role of the same PK2 in mood 552 
regulation: intracerebroventricular injection of PK2 leads to increase of anxiety and 553 
depressive like behavior while mice deficient in PK2 displayed reduced anxiety and 554 
depression (Li et al., 2009). At our evaluation time we observed low levels of PK2 in 555 
the same supraspinal areas and in HPC we also observed a downregulation of glial 556 
markers. This condition, probably due to an initial loss of glial cells, suggests the 557 
onset of a neuroinflammatory/ neurotoxic condition (Czèh et al., 2006; Banasr et al., 558 
2010) in brain tissues. PC1 treatment can counteract this process by normalizing 559 
GFAP and PK2 levels in HPC, suggesting that astrocytes may be important 560 
producers of PK2 not only in spinal cord (Maftei et al., 2014; Moschetti et al., 2019), 561 
but also in the hippocampus. In a recent pre-clinical study on Paclitaxel (Toma et al., 562 
2017) it was detected a temporal shift between the onset of pain and emotional-like 563 
deficits. On the basis of these results, we can not exclude that the precocious 564 
biochemichal alterations observed in brain tissues could lead to the development of 565 
altered affective like behavior at longer evaluation times or in presence of multiple 566 
cycles of VCR.   567 
In conclusion this study described a role of PK2 in vincristine-induced neuropathic 568 
pain and suggests that the antagonism of PK system could represent a common 569 
strategic target to manage chemotherapy-induced neuropathic pain counteracting 570 
the development and progression of a neuroinflammatory condition. 571 
 572 
 573 
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 833 
Legends 834 
FIGURE 1: Timeline representing the experimental design.  835 
VCR: Vincristine sulfate 836 
PC1: PK-Rs antagonist 837 
FIGURE 2: Effect of VCR treatment on hypersensitivity (allodynia and hyperalgesia) and 838 
affective behavior (anxiety and depressive like behavior). Effect of PK-Rs antagonist (PC1) 839 
on hypersensitivity. 840 
a-c: Panels a, b and c show the time course development of mechanical (panel a) and 841 
thermal (panel b) allodynia as well as thermal hyperalgesia (panel c) in mice chronically 842 
treated with vincristine for 14 consecutive days (VCR; 0.1mg/ kg, once a day). In the same 843 
panels it is reported the effect of PC1 treatment. PC1 was administered (s.c. 150μg/kg twice 844 
a day) for 7 days starting from day 7 (established hypersensitivity) until the end of VCR 845 
schedule, day 14. Data are presented as mean±SEM of 18 mice/group. Statistical analysis 846 
was performed by mean of Two way-ANOVA analysis of variance with repeated measures 847 
followed by Bonferroni’s post test. Treatment: F(2, 51), panel a= 296.9 ; panel b= 75.18; 848 
panel c= 424. 8, p<0.0001. Time: F(4, 204) panel a=165.9, panel b=46.19, panel c=121.8, 849 
p<0.0001. Interaction: F(8, 204) panel a= 105.8, panel b=18.73, panel c=41.65, p<0.0001. 850 
Bonferroni post test: ***p<0.001 vs CTR (saline treated mice); °°° p< 0.001 vs VCR; ++p<0.01, 851 
+++p<0.001 vs VCR mice at the previous time point. d-i: Panels d, e, f and g show the effect of 852 
14 days of VCR treatment on anxiety-like behavior, evaluated in an anxiety like cohort of 853 
animals, by means of open field (panel d), novelty suppressed feeding (panel e), marble 854 
burying (panel f) and dark/light box test (panel g). At the same time (day 14) depressive-like 855 
behavior was tested in a depression-like cohort of mice by using the forced swim test (panel 856 
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h) and sucrose preference test (panel i). Data are presented as mean± SEM of 8 animals per 857 
group. Statistical analysis was performed by means of two-tailed unpaired T-test. 858 
FIGURE 3: PK system and neuroinflammatory markers in DRG. 859 
mRNA levels of PK system members and of neuroinflammatory markers were measured in 860 
DRG by using Real Time-qPCR. Evaluations were performed after 7 days of chronic VCR 861 
administration in CTR and VCR mice and at the end of the chemotherapeutic schedule (day 862 
14) in CTR, VCR and VCR + PC1 mice. Results were expressed in relation to GAPDH and 863 
presented as fold-increases over the levels of CTR animals (at the same time point). Data are 864 
presented as mean±SEM from 5-8 mice per group. At day 7, statistical analysis was 865 
performed by means of unpaired T-test while at day 14 by One way-Anova analysis of 866 
variance followed by Bonferroni’s post test. a-c: Panels a, b and c report the mRNA levels of 867 
PK2, PK-R1 and PK-R2 respectively. 7 days: PK2: t=1.21, p=0.26; PK-R1: t=2.616, p=0.0357; 868 
PK-R2: t=4.894, p=0.0004. Day 14:PK2: F(2,13)=8.482, p=0.0044; PK-R1: F(2,12)=8.715, p=0.0046; 869 
PK-R2: F (2,21) =29.17, p<0.0001. d-g:  Panels d, e and f represent respectively the mRNA 870 
levels of the proinflammatory cytokines IL-1β (7 days, t=2.995, p=0.0156; 14 days F(2,12) 871 
=24.16, p<0.0001), TNF-α (7 days, t=0.034, p=0.97; 14 days F(2,12) =17.27,p=0.0003) and IL-6 872 
(7 days, t=0.18, p=0.86; 14 days F(2,12) =25.85 , p<0.0001) while panel g reports that of the 873 
anti-inflammatory cytokine IL-10 (7 days, t=1.28, p=0.237; 14 days F(2,15) =28.09, p<0.0001. 874 
h-m: mRNA levels of TLR4 (panel h, 7 days, t=2.7, p=0.028; 14 days F(2,22) =11.19, p=0.0004 ), 875 
CD68 (panel i, 7 days, t=2.744, p=0.026; 14 days F(2,21) =10.66, p=0.0006) and CD11b (panel l, 876 
7 days, t=0.745, p=0.478; 14 days F(2,14) =7.196, p=0.0071) and of the marker of neuronal 877 
damage ATF3 (panel m, 7 days, t=5.35, p=0.0005; 14 days F(2,15) =6.897, p=0.0075). 878 
Bonferroni post test:  *p<0.05, **p<0.01, ***p<0.001 vs vehicle/CTR (at the same time 879 
point); °p<0.05, °°p<0.01, °°°p<0.001 vs VCR day 14.  880 
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 881 
 882 
FIGURE 4: PK system and neuroinflammatory markers in spinal cord. 883 
mRNA levels of PK system members and of neuroinflammatory markers were measured in 884 
spinal cord by using Real Time-qPCR. Evaluations were performed after 7 days of chronic 885 
VCR administration in CTR and VCR mice and at the end of the chemotherapeutic schedule 886 
(day 14) in CTR, VCR and VCR + PC1mice. Data are presented as mean±SEM from 5-8 mice 887 
per group. At day 7, statistical analysis was performed by means of two tails unpaired T-test 888 
while at day 14 by One way-Anova analysis of variance followed by Bonferroni’s post test. 889 
a-c: Panels a, b and c report the mRNA levels of PK2, PK-R1 and PK-R2 respectively. 7 days: 890 
PK2: t=1.938, p=0.108; PK-R1: t=4.227, p=0.0127; PK-R2: t=3.685, p=0.021. Day 14: PK2: 891 
F(2,15) =18.82, p<0.0001; PK-R1: F(2,12) =21.7, p=0.0001; PK-R2: F (2,12)=27, p<0.0001. d-g: 892 
Panels d, e and f represent respectively the mRNA levels of the proinflammatory cytokines 893 
IL-1β (7 days, t=0.661, p=0.526; 14 days F(2,21) =10.44,p=0.0007), TNF-α (7 days, t=0.252, 894 
p=0.808; 14 days F(2,21) =11.12, p=0.0005), and IL-6 (7 days, t=1.633, p=0.17; 14 days F(2,12) 895 
=1.804, p=0.206), while panel g reports that of the anti-inflammatory cytokine IL-10 (7 days, 896 
t=0.0427, p=0.967; 14 days F(2,15) =0.0814, p=0.92). h-n: mRNA levels of TLR4 (panel h, 7 897 
days, t=0.885, p=0.412; 14 days F(2,12) =5.886, p=0.0165), of the glial markers: CD68 (panel i, 898 
7 days, t=3.632, p=0.007; 14 days F(2,12) =21.52, p=0.0001), CD11b (panel l, 7 days, t=1.234, 899 
p=0.279; 14 days F(2,12) =6.808, p=0.011) and GFAP (panel m, 7 days, t=0.520, p=0.618; 14 900 
days F(2,12) =28.6, p<0.0001) and of the marker of neuronal damage ATF3 (panel n, 7 days, t= 901 
1.924, p=0.122; 14 days F(2,12) =26.13, p<0.0001). Bonferroni’s post:  *p<0.05, **p<0.01, 902 
***p<0.001 vs CTR (at the same time point); °p<0.05, °°p< 0.01, °°°p<0.001 vs VCR day 14. 903 
 904 
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 905 
FIGURE 5: PK system and neuroinflammatory markers in prefrontal cortex and 906 
hippocampus. 907 
mRNA levels of PK system members and of neuroinflammatory markers measured at the 908 
end of the chemotherapeutic schedule (day 14) in prefrontal cortex (PFC) and hippocampus 909 
(HPC) of CTR, VCR and VCR + PC1 mice by using Real Time-qPCR. Results were expressed in 910 
relation to GAPDH and presented as fold-increases over the levels of CTR animals. Data are 911 
presented as  mean±SEM of 5 mice/ group. Statistical analysis were performed using One 912 
way-Anova analysis of variance followed by Bonferroni’s post test. a-c: Panels a, b and c 913 
report the mRNA levels of PK2 (PFC: F(2,12) =7.198, p=0.0088; HPC: F(2,12) =22.36, p<0.0001), 914 
PK-R1 (PFC: F(2,12) =3.406, p=0.067; HPC: F(2,12) =2.23, p=0.15) and PK-R2 (PFC: F(2,12) =6.688, 915 
p=0.011; HPC: F(2,12) =0.787, p=0.478) respectively. d-g: mRNA levels of the proinflammatory 916 
cytokines IL-1β (d ), TNF-α (e) and IL-6 (f) and of the anti-inflammatory cytokine IL-10 (g). h-l: 917 
mRNA levels of the glial markers: CD68 (panel h, PFC: F (2,12) =0.997, p=0.398; HPC: F (2,12) 918 
=4.68, p=0.03), CD11b (panel i, PFC: F(2,12) =2.954, p=0.0906; HPC: F(2,12) =5.371, p=0.022) 919 
and GFAP (panel l, PFC: F(2,12)=0.455, p=0.645; HPC: F(2,12) =23.69, p<0.0001). Bonferroni post 920 
test: *p<0.05, **p<0.01 vs CTR; °p<0.05, °°p<0.01 vs VCR. 921 
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